Does Blue Cross Blue Shield of Massachusetts Cover Forteo?

What Forteo Is and Why Women Are the Primary Patients

Forteo is the brand name for teriparatide, a synthetic fragment of parathyroid hormone (PTH 1-34) that your body uses to build new bone rather than simply slow bone loss. The FDA approved teriparatide for postmenopausal women with osteoporosis at high fracture risk, and the vast majority of prescriptions go to women. That is not an accident: women lose up to 20% of their bone density in the five to seven years after menopause, a rate driven by the sharp drop in estrogen that removes its protective effect on osteoclasts.

Unlike bisphosphonates (alendronate, risedronate, zoledronic acid) or denosumab, which are antiresorptive agents that slow bone breakdown, teriparatide is anabolic. It stimulates osteoblasts to form new bone matrix. In the landmark Fracture Prevention Trial (FPT), teriparatide 20 mcg daily reduced new vertebral fractures by 65% and non-vertebral fractures by 53% compared with placebo in postmenopausal women over a median of 21 months. That trial enrolled 1,637 women, making the postmenopausal female dataset the strongest available.

How Teriparatide Is Administered

You inject 20 mcg subcutaneously once daily using a pre-filled pen device. The pen contains a 28-day supply. Treatment is capped at 24 months lifetime because of a historical concern about osteosarcoma observed at very high doses in rats, though no causal link to human osteosarcoma has been established in post-marketing data. After completing teriparatide, you transition to an antiresorptive agent to preserve the gains.

Female-Specific Pharmacokinetics

Teriparatide reaches peak serum concentration roughly 30 minutes after subcutaneous injection and has a half-life of approximately one hour. Body weight and renal function affect clearance more than sex per se, but women prescribed this drug are disproportionately older, low-weight, and may have age-related reductions in creatinine clearance that slow elimination slightly. Your prescriber should review your renal function before initiating therapy.

Does BCBS Massachusetts Actually Cover Forteo?

Yes, BCBS Massachusetts does list teriparatide on its specialty formularies, but coverage is conditional on meeting specific clinical criteria. The word "covers" can mislead. Being on the formulary means the drug is eligible for benefits; it does not mean you pay nothing or that approval is automatic.

Commercial Plans (Employer-Sponsored and Individual Market)

Most BCBS MA commercial plans place Forteo on a Specialty Tier (typically Tier 4 or Tier 5). Cost-sharing at these tiers commonly runs 20-30% coinsurance after your deductible, which on a $3,400 list-price drug translates to $680-$1,020 per fill even with coverage. Prior authorization is required on every commercial plan that covers it.

Medicare Advantage Plans

If you are enrolled in a BCBS MA Medicare Advantage plan, teriparatide falls under Part D. CMS requires Medicare Part D plans to cover osteoporosis drugs, but the formulary tier and cost-sharing are plan-specific. In 2024, the Medicare Part D out-of-pocket cap is $8,000, which affects how much you spend total across the plan year.

MassHealth (Medicaid) Managed by BCBS MA

If your coverage is MassHealth CarePlus or a BCBS MA-administered Medicaid product, teriparatide coverage exists but is subject to the Massachusetts MassHealth preferred drug list and prior authorization criteria set by the state, not by BCBS MA alone.

Prior Authorization: What BCBS MA Looks For

Prior authorization (PA) is the approval process where your prescriber submits clinical documentation proving the drug is medically necessary for you specifically. BCBS MA's PA criteria for teriparatide generally require all of the following:

• Diagnosis of osteoporosis, defined by DXA T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip, OR a documented low-trauma (fragility) fracture
• High fracture risk, often quantified with a FRAX score showing a 10-year major osteoporotic fracture probability at or above the intervention threshold in current NOF/Endocrine Society guidelines
• Step therapy: documentation that you have tried and either failed or cannot tolerate at least one bisphosphonate (alendronate, risedronate, ibandronate, or zoledronic acid) or another approved antiresorptive agent
• Prescriber specialty: the PA is more straightforward when prescribed by an endocrinologist, rheumatologist, or metabolic bone specialist, though primary care prescribers can also obtain approval
• No contraindications: Paget disease of bone, unexplained alkaline phosphatase elevation, prior radiation involving the skeleton, bone metastases, or hypercalcemia are contraindications that will block approval

The authorization period is typically 12 months, with a renewal PA required if you continue into a second year.

What Counts as "Step Therapy Failure"

Step therapy failure means you took the first-line agent at an adequate dose for an adequate duration and your bone density continued to decline, you sustained a fracture on therapy, or you experienced intolerance or a contraindication. Intolerance examples include bisphosphonate-related esophageal problems, atypical femur fracture on long-term bisphosphonate therapy, or osteonecrosis of the jaw. Your prescriber documents this in the PA letter. Being "bothered" by weekly pill-taking or GI upset that resolved does not typically meet the bar; documented clinical failure or a meaningful adverse event does.

Life-Stage Considerations: Who Gets Prescribed Forteo and Why It Matters for Coverage

Postmenopausal Women (the Primary Indication)

This is where the clinical data are strongest. The Endocrine Society Clinical Practice Guideline on osteoporosis in postmenopausal women recommends teriparatide for women with very high fracture risk, defined as a prior vertebral or hip fracture, T-score at or below -3.0, or a FRAX 10-year major fracture probability above 30%. BCBS MA PA criteria align closely with these thresholds. If you are postmenopausal with a documented vertebral fracture and a T-score of -2.8 or lower, you have a strong case for approval.

Perimenopausal Women

Perimenopause is the transition stage, typically spanning four to seven years before your final menstrual period, when estrogen begins fluctuating and bone loss accelerates. Most perimenopausal women do not yet meet the severity threshold for teriparatide. If you are perimenopausal with bone loss driven by secondary causes (celiac disease, inflammatory bowel disease, glucocorticoid use, premature ovarian insufficiency), the prescriber must document the secondary etiology clearly because BCBS MA will scrutinize the diagnosis more carefully in someone who is still menstruating.

Women with Glucocorticoid-Induced Osteoporosis

The FDA also approved teriparatide for glucocorticoid-induced osteoporosis in men and women at high fracture risk on chronic steroid therapy. Women with conditions requiring long-term prednisone (rheumatoid arthritis, lupus, inflammatory bowel disease, asthma) fall into this category. BCBS MA covers this indication, though step therapy still typically applies unless fracture risk is extreme.

Premenopausal Women

Teriparatide is not FDA-approved for premenopausal osteoporosis. Coverage for off-label use is harder to obtain. BCBS MA may deny on the basis of off-label status unless your prescriber can cite strong clinical evidence and document why no approved agent is appropriate. The American Society for Bone and Mineral Research has published guidance on premenopausal osteoporosis that distinguishes idiopathic premenopausal osteoporosis from secondary causes, and this document can support a PA appeal.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

This section is required reading if there is any chance you could become pregnant.

Pregnancy

Forteo is contraindicated in pregnancy. Teriparatide has not been studied in pregnant women. Animal reproduction studies showed fetal harm at doses producing systemic exposures above those used clinically. The FDA label classifies teriparatide as contraindicated in pregnancy. If you are of reproductive age and prescribed teriparatide, you must use reliable contraception throughout treatment and for a clinically reasonable interval after stopping, given that the drug clears within hours but bone changes persist.

If you become pregnant while on teriparatide, stop the drug immediately and contact your prescriber. Report the exposure to the Eli Lilly pregnancy registry (1-800-545-5979) so data on outcomes can be collected.

Lactation

Teriparatide transfer into human breast milk has not been studied. Because it is a peptide hormone, it is likely degraded in the infant's gastrointestinal tract even if small amounts transfer. However, given the lack of data, the FDA label advises against use during breastfeeding. Most women prescribed teriparatide are postmenopausal and not breastfeeding, but premenopausal or perimenopausal women on treatment should discuss the risk-benefit with their provider.

Postpartum Bone Loss

Pregnancy and lactation both cause transient, significant bone loss that typically reverses after weaning. A woman who presents with a fragility fracture in the postpartum period may undergo evaluation for rare conditions like pregnancy- and lactation-associated osteoporosis (PLO). There are case reports of teriparatide use in PLO, and a 2022 case series published in JCEM documented vertebral fracture healing and BMD recovery with teriparatide in women with PLO, but this is an off-label use and coverage is far from guaranteed through BCBS MA.

Biosimilar Bonsity: A Coverage Angle Worth Knowing

Bonsity (teriparatide-tjwp, Teva) received FDA biosimilar approval in 2021 and launched at a lower list price than Forteo. BCBS MA formularies may prefer Bonsity over Forteo if the plan has designated it the preferred teriparatide product. If your PA is approved but your pharmacy says Forteo is not covered, ask specifically whether Bonsity is the preferred alternative on your plan. Clinically, the two are interchangeable; biosimilar designation requires demonstration of no meaningful difference in safety and efficacy.

How to Appeal a BCBS MA Denial

Denials happen. They are not final. Here is a practical sequence:

1. Request the denial reason in writing. BCBS MA must provide the specific clinical criteria you failed to meet.
2. Ask your prescriber for a peer-to-peer review. A physician at BCBS MA reviews the case directly with your treating clinician. Peer-to-peer overturns a meaningful share of specialty drug denials.
3. File a formal internal appeal. You have the right to an internal appeal within 180 days of the denial under Massachusetts state insurance law.
4. Request an expedited appeal if you have a recent fracture or rapidly declining bone density. Expedited appeals must be resolved within 72 hours.
5. File an external appeal. Massachusetts requires independent external review by an accredited IRO (Independent Review Organization) if the internal appeal fails. The Massachusetts Division of Insurance oversees this process.
6. Contact your prescriber about manufacturer assistance. Eli Lilly's Lilly Cares Foundation offers patient assistance for Forteo for income-eligible patients, and the Lilly Savings Card may reduce cost-sharing for commercially insured patients who do not qualify for subsidies.

A Practical Framework for Getting Forteo Covered Through BCBS MA

The following five-step framework is specific to BCBS MA and distills what separates successful PAs from denied ones in clinical practice:

Step 1: Get a DXA with T-scores at all three sites. A T-score at one site may miss severity at another. BCBS MA reviewers look for the worst T-score across lumbar spine, femoral neck, and total hip.

Step 2: Calculate FRAX with bone density entered, not estimated. A FRAX calculation that incorporates your actual femoral neck T-score produces a more accurate 10-year fracture probability and strengthens the PA letter. The FRAX tool is freely available from the University of Sheffield.

Step 3: Document bisphosphonate history precisely. Include dates, doses, duration, and the specific reason for discontinuation or failure. Vague statements ("patient tried alendronate") fail; "patient received alendronate 70 mg weekly for 36 months with progressive lumbar spine bone loss from -2.7 to -3.1 T-score on repeat DXA" succeeds.

Step 4: Have a specialist co-sign or author the PA letter. Endocrinology or metabolic bone specialty involvement reduces denial rates in practice, even when the primary care provider manages the prescription.

Step 5: Include vertebral imaging if available. A VFA (vertebral fracture assessment) from DXA or a spine X-ray showing prevalent vertebral fracture, even if asymptomatic, moves you into the "very high risk" category that meets BCBS MA criteria most clearly.

Who This Treatment Is Right For and Who Should Look Elsewhere

Women Most Likely to Benefit and Get Coverage Approved

• Postmenopausal women with a T-score at or below -2.5 plus one or more fragility fractures
• Women with T-score at or below -3.0 even without a prior fracture
• Women who have been on bisphosphonates for three or more years and had a fracture or continued bone loss on therapy
• Women with glucocorticoid-induced osteoporosis at high fracture risk taking prednisone 5 mg or more daily for three or more months

Women for Whom Forteo Is Likely Not the Right First Step

• Women with mild osteopenia (T-score between -1.0 and -2.5) and low FRAX score
• Women who have not yet tried antiresorptive therapy unless there is a documented contraindication or very high initial fracture risk
• Premenopausal women without a documented secondary cause of severe bone loss
• Women with a history of bone metastases, hypercalcemia, or prior skeletal radiation (absolute contraindications)

Cost Without Coverage: Manufacturer and Third-Party Assistance

If coverage is denied or your cost-sharing remains high, real financial pathways exist:

• Lilly Cares Patient Assistance Program: Free drug for income-eligible patients (generally at or below 400% federal poverty level) who are uninsured or underinsured
• Lilly Savings Card: Commercially insured patients may pay as low as $5 per fill through the manufacturer copay card; check eligibility at LillyCares.com
• Teva/Bonsity patient support: Teva offers similar assistance programs for Bonsity; the biosimilar list price is lower, making cost-sharing lower even at the same coinsurance percentage
• GoodRx and specialty pharmacy discounts: Typically save less on specialty biologics than on small-molecule drugs, but worth checking; the 28-day pen device is the only formulation available

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) maintains a resource list of patient assistance programs updated periodically for osteoporosis medications.

What Happens After 24 Months

Teriparatide treatment is limited to 24 cumulative months. After you finish, your provider will transition you to an antiresorptive agent, typically zoledronic acid (annual infusion) or denosumab (every-six-month injection), to prevent rapid reversal of the bone gains. A 2019 study in NEJM (DATA-Switch) showed that transitioning from teriparatide to denosumab produced further BMD gains, while those who stopped without antiresorptive follow-up lost a substantial portion of the benefit within 12 months.

BCBS MA generally covers both zoledronic acid and denosumab, typically at lower tiers than teriparatide, which makes the post-Forteo plan more affordable for most women.